Daily Archives: June 18, 2020

Philips announces collaboration with American Telemedicine Association to further commitment to telehealth

June 18, 2020

  • Two leading organizations join forces to drive future telehealth strategies across hospital settings into the home propelled by COVID-19
  • Jeroen Tas, Chief Strategy & Innovation Officer at Philips to deliver executive spotlight address at Annual ATA Virtual Conference

Amsterdam, the Netherlands and Washington, DC – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute and home care settings. The continued collaboration spotlights the growing adoption and momentum in telehealth amidst COVID-19, and the need to convey the exponential shift to telehealth capabilities.

The COVID-19 pandemic has increased the share of Americans participating in telehealth from 11% in 2019 to 46% today, with healthcare systems reporting a 50 to 175-fold increase in telehealth volume compared to pre-pandemic levels [1]. As the world begins to move from the first wave of reactive care, into a more proactive phase and beyond, virtual care solutions are supporting the recovery of COVID patients as they transition through their care journey, and non-COVID patients as they return to elective surgeries, diagnoses, prevention and treatments that have been put on hold since the onset of the pandemic.

“There is no better time for Philips to team with the ATA. Philips is creating proactive, AI-powered solutions to improve patient monitoring, precision diagnosis and clinical workflows at every point along the continuum. This directly aligns with our vision for telehealth — to drive the transformation of health by integrating virtual care from the hospital to physician offices and the home,” said Ann Mond Johnson, CEO, the ATA. “Major industry players like Philips joining the ATA reconfirms the importance of telehealth and creates important new opportunities to deliver quality care whenever and wherever it’s needed.”

“Philips has been a leader in telehealth across acute care and post-acute care settings in the hospital and in the home for over three decades, helping health systems deploy and scale telehealth solutions to help improve patient outcomes, enhance patient and staff experience and lower care costs,” said Roy Jakobs, Chief Business Leader Connected Care, member of the Executive Committee at Royal Philips. “Our alignment with ATA will help promote strong  growth and faster adoption of telehealth and policy changes escalated during the COVID crisis as we pivot to innovate ‘virtual first’ strategies to support hospitals, payers, and patients across care settings, including digital health technologies to support healthy living in the home.”

Expanding virtual connected care through partnership and innovation
COVID-19 has propelled digital technology to the forefront as healthcare systems rapidly expand telehealth, including virtual care, remote patient monitoring, data analytics and medical record-sharing capabilities to care for patients with COVID-19. In response to the pandemic, Philips has been working with customers around the world to rapidly develop and deploy scalable telehealth solutions to support frontline care professionals and their patients. Philips recently received 510(k) clearance from the Food and Drug Administration for its wireless wearable biosensor (Philips Biosensor BX100) to help manage confirmed and suspected COVID-19 patients in the hospital.  The wearable biosensor enhances clinical surveillance as part of the Philips patient deterioration detection solution to help clinicians detect risk so they can intervene earlier and help improve care for patients in lower acuity care areas.

The Philips Virtual Connected Care Ecosystem comprises people, processes, and technology. At the core of the platform are three Philips FDA-cleared, vendor agnostic solutions currently utilized to provide remote critical care to patients in the hospital and at home including:

  • FDA-cleared Tele-ICU software (eCare Manager) with AI-enabled decision support algorithms to enable critical care clinicians to work virtually coordinating with on-site clinical staff to provide care to COVID-19 patients from the hospital into the home;
  • Cloud-based software platform (IntelliSpace Corsium) provides real-time patient monitoring tracking during patient transport;
  • Patient centered apps (eCare Coordinator for providers/eCare Companion for patients) deployed in a home environment using mobile IOT (Internet of Things) monitoring devices to allow healthcare providers to monitor physiologic survey data and communicate directly with the patients they are providing care to as needed.

Telehealth expanding access to care for millions of U.S. veterans
Philips has partnered with The U.S. Department of Veterans Affairs (VA), The American Legion and Veterans of Foreign Wars (VFW) on Advancing Telehealth through Local Access Stations known as the ATLAS Program, bringing care to Veterans where and when they need it most.  Launching in Eureka, Montana, followed by Springfield, Virginia, Atlas kicked off in 2019 with 10 pilot sites to be installed before the end of 2020. Philips has also taken the current  configuration being used for the ATLAS Program to now create the commercial Philips Virtual Care Station that will further expand access to care through non-traditional locations such as retail health, community and university environments.

ATA 2020 Annual Virtual Conference and Expo
The 2020 ATA Annual conference will take place virtually, beginning June 22 – 26, 2020. Participants will have access to keynote discussions and panel sessions ranging in topics from interoperability and cybersecurity, to remote patient monitoring and disparity within telehealth offerings.  On June 24, at 11:00AM – 11:20AM ET, Jeroen Tas, Chief Innovation & Strategy Officer at Royal Philips will discuss how Philips responded to the COVID-19 pandemic and worked with customers around the world in developing telehealth  solutions to support front-line care professionals. He will also share his vision on how healthcare leaders should embrace new ways of thinking to make possible digital, more modular and scalable, telehealth solutions.

[1] McKinsey https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

Gina Cella
American Telemedicine Association
Tel: +1 781-799-3137
E-mail: gcella@cellapr.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About the ATA
As the only organization completely focused on advancing telehealth, the ATA is committed to ensuring that everyone has access to safe, affordable, and appropriate care when and where they need it, enabling the system to do more good for more people. ATA represents a broad and inclusive member network of technology solution providers and payers, as well as partner organizations and alliances, working to advance industry adoption of telehealth, promote responsible policy, advocate for government and market normalization, and provide education and resources to help integrate virtual care into emerging value-based delivery models. @americantelemed #gotelehealth #ATApolicy

Attachments

Philips announces collaboration with American Telemedicine Association to further commitment to telehealth

June 18, 2020

  • Two leading organizations join forces to drive future telehealth strategies across hospital settings into the home propelled by COVID-19
  • Jeroen Tas, Chief Strategy & Innovation Officer at Philips to deliver executive spotlight address at Annual ATA Virtual Conference

Amsterdam, the Netherlands and Washington, DC – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute and home care settings. The continued collaboration spotlights the growing adoption and momentum in telehealth amidst COVID-19, and the need to convey the exponential shift to telehealth capabilities.

The COVID-19 pandemic has increased the share of Americans participating in telehealth from 11% in 2019 to 46% today, with healthcare systems reporting a 50 to 175-fold increase in telehealth volume compared to pre-pandemic levels [1]. As the world begins to move from the first wave of reactive care, into a more proactive phase and beyond, virtual care solutions are supporting the recovery of COVID patients as they transition through their care journey, and non-COVID patients as they return to elective surgeries, diagnoses, prevention and treatments that have been put on hold since the onset of the pandemic.

“There is no better time for Philips to team with the ATA. Philips is creating proactive, AI-powered solutions to improve patient monitoring, precision diagnosis and clinical workflows at every point along the continuum. This directly aligns with our vision for telehealth — to drive the transformation of health by integrating virtual care from the hospital to physician offices and the home,” said Ann Mond Johnson, CEO, the ATA. “Major industry players like Philips joining the ATA reconfirms the importance of telehealth and creates important new opportunities to deliver quality care whenever and wherever it’s needed.”

“Philips has been a leader in telehealth across acute care and post-acute care settings in the hospital and in the home for over three decades, helping health systems deploy and scale telehealth solutions to help improve patient outcomes, enhance patient and staff experience and lower care costs,” said Roy Jakobs, Chief Business Leader Connected Care, member of the Executive Committee at Royal Philips. “Our alignment with ATA will help promote strong  growth and faster adoption of telehealth and policy changes escalated during the COVID crisis as we pivot to innovate ‘virtual first’ strategies to support hospitals, payers, and patients across care settings, including digital health technologies to support healthy living in the home.”

Expanding virtual connected care through partnership and innovation
COVID-19 has propelled digital technology to the forefront as healthcare systems rapidly expand telehealth, including virtual care, remote patient monitoring, data analytics and medical record-sharing capabilities to care for patients with COVID-19. In response to the pandemic, Philips has been working with customers around the world to rapidly develop and deploy scalable telehealth solutions to support frontline care professionals and their patients. Philips recently received 510(k) clearance from the Food and Drug Administration for its wireless wearable biosensor (Philips Biosensor BX100) to help manage confirmed and suspected COVID-19 patients in the hospital.  The wearable biosensor enhances clinical surveillance as part of the Philips patient deterioration detection solution to help clinicians detect risk so they can intervene earlier and help improve care for patients in lower acuity care areas.

The Philips Virtual Connected Care Ecosystem comprises people, processes, and technology. At the core of the platform are three Philips FDA-cleared, vendor agnostic solutions currently utilized to provide remote critical care to patients in the hospital and at home including:

  • FDA-cleared Tele-ICU software (eCare Manager) with AI-enabled decision support algorithms to enable critical care clinicians to work virtually coordinating with on-site clinical staff to provide care to COVID-19 patients from the hospital into the home;
  • Cloud-based software platform (IntelliSpace Corsium) provides real-time patient monitoring tracking during patient transport;
  • Patient centered apps (eCare Coordinator for providers/eCare Companion for patients) deployed in a home environment using mobile IOT (Internet of Things) monitoring devices to allow healthcare providers to monitor physiologic survey data and communicate directly with the patients they are providing care to as needed.

Telehealth expanding access to care for millions of U.S. veterans
Philips has partnered with The U.S. Department of Veterans Affairs (VA), The American Legion and Veterans of Foreign Wars (VFW) on Advancing Telehealth through Local Access Stations known as the ATLAS Program, bringing care to Veterans where and when they need it most.  Launching in Eureka, Montana, followed by Springfield, Virginia, Atlas kicked off in 2019 with 10 pilot sites to be installed before the end of 2020. Philips has also taken the current  configuration being used for the ATLAS Program to now create the commercial Philips Virtual Care Station that will further expand access to care through non-traditional locations such as retail health, community and university environments.

ATA 2020 Annual Virtual Conference and Expo
The 2020 ATA Annual conference will take place virtually, beginning June 22 – 26, 2020. Participants will have access to keynote discussions and panel sessions ranging in topics from interoperability and cybersecurity, to remote patient monitoring and disparity within telehealth offerings.  On June 24, at 11:00AM – 11:20AM ET, Jeroen Tas, Chief Innovation & Strategy Officer at Royal Philips will discuss how Philips responded to the COVID-19 pandemic and worked with customers around the world in developing telehealth  solutions to support front-line care professionals. He will also share his vision on how healthcare leaders should embrace new ways of thinking to make possible digital, more modular and scalable, telehealth solutions.

[1] McKinsey https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

Gina Cella
American Telemedicine Association
Tel: +1 781-799-3137
E-mail: gcella@cellapr.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About the ATA
As the only organization completely focused on advancing telehealth, the ATA is committed to ensuring that everyone has access to safe, affordable, and appropriate care when and where they need it, enabling the system to do more good for more people. ATA represents a broad and inclusive member network of technology solution providers and payers, as well as partner organizations and alliances, working to advance industry adoption of telehealth, promote responsible policy, advocate for government and market normalization, and provide education and resources to help integrate virtual care into emerging value-based delivery models. @americantelemed #gotelehealth #ATApolicy

Attachments

PRA Health Sciences ready to navigate RACE Act requirements for pediatric oncology

U.S. law requiring clinical research for pediatric oncology treatments goes into effect mid-August 2020

RALEIGH, N.C., June 18, 2020 (GLOBE NEWSWIRE) — Between 2007-2017, 78 novel adult cancer agents were approved by the U.S. Food and Drug Administration,1 but none of those drugs were researched to determine effectiveness for pediatric cancers.

That is about to change on August 18 when the RACE Act – The Research to Accelerate Cures and Equity for Children Act – goes into effect. Passed in 2017, the RACE Act amends the existing PREA – Pediatric Research Equity Act – and eliminates the exemption from PREA requirements for cancer drugs that have orphan status. The new law requires pediatric evaluation of new drugs and biologics intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of pediatric cancer.

Clinical research companies and their pediatric research specialists, including PRA Health Sciences, will be called on to support pharmaceutical and biotech companies as they sponsor the required research for pediatric oncology indications.

“We are now 60 days away from the RACE Act going into effect, which has created a scramble to develop pediatric study plans for oncology studies,” said Dr. Mark Sorrentino, VP, The Center for Pediatric Clinical Development at PRA Health Sciences. “Here at PRA,
we have been preparing for the RACE Act since it was passed in 2017, so we are able to quickly and effectively support our clients and sponsors looking to conduct this research. We have brought together a highly credentialed team internally to serve as hands-on consultants in the development and execution of pediatric research plans.”

PRA’s Center for Pediatric Clinical Development and the team working on the RACE Act implementation include Dr. Sorrentino as well as Dr. Martine Dehlinger-Kremer, VP, Scientific Affairs, Pediatric Subject Matter Expert; Dr. Jacqui Whiteway, Senior Pediatric Strategy Liaison; Jo Dewhurst, LLB Dip; and Missy Hansen, MSN, APRN, CNP-Pediatrics, Pediatric Strategy Liaison. Together, with the addition of dozens of other PRA researchers and pediatric specialists, this designated team of experts is ready to utilize their collective experience in pediatric clinical development to support RACE Act-focused initiatives.

“Parents and pediatric oncologists need to have confidence that the therapies and treatments they are giving to their children are safe and effective for fighting cancer in pediatric patients,” Dr. Dehlinger-Kremer said. “The RACE Act is pushing all of us – drug developers, researchers, and medical care teams – to find the best treatments possible for children and their families, and to develop treatments that are specifically tailored to children.”

With the RACE Act going into effect, the law has caught up with the critical need for drug developers to focus on pediatric oncology.

  • Since 1980, only four oncology drugs were first approved for use in children2
  • Only 4 percent of funding spent on cancer research is directed toward childhood cancer3
  • Cancer drugs approved by the FDA take a median of 6.5 years to go from first clinical trial in adults to the first trial in children4
  • While considered a rare condition, 46 children are diagnosed with cancer each day5 and those patients, their families, and their medical teams need more treatments suitable for pediatric indications

“From a research perspective, there is so much more we can do to improve kids’ lives,” Dr. Sorrentino said. “PRA has conducted more than 130 pediatric studies in the last five years, and our promise, to the kids and their families, is to work quickly and safely, specifically with them in mind, to develop treatment options that will be effective for our smallest patients. It’s going to take a collective team effort between drug developers and researchers – we are ready for that challenge.”

For more information on the RACE Act, visit https://prahs.com/centers/the-center-for-pediatric-clinical-development/race-act. If you’d like to speak with one of PRA’s pediatric oncology experts, please reach out to us at https://prahs.com/contact/capabilities.

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

MEDIA INQUIRIES: Laurie Hurst, Director, Communications and Public Relations
hurstlaurie@prahs.com | +1 (919) 786-8435

References

  1. Hwang T.J., et al. Pediatric trials for cancer therapies with targets potentially relevant to pediatric cancers. Journal National Cancer Institute (2020) 112(3): djz207.
  2. Coalition Against Childhood Cancer. Childhood Cancer Fact Library (2017). https://cac2.org/childhood-cancer-fact-library-2017/#:~:text=Since%201980%2C%20only%20four%20drugs,use%20in%20high%2Drisk%20neuroblastoma.
  3. https://nationalpcf.org/facts-about-childhood-cancer/
  4. Dylan V. Neel, David S. Shulman, Steven G. DuBois. Timing of first-in-child trials of FDA-approved oncology drugs. European Journal of Cancer, 2019; 112: 49 DOI: 10.1016/j.ejca.2019.02.011.
  5. www.childrenscause.org

PRA Health Sciences ready to navigate RACE Act requirements for pediatric oncology

U.S. law requiring clinical research for pediatric oncology treatments goes into effect mid-August 2020

RALEIGH, N.C., June 18, 2020 (GLOBE NEWSWIRE) — Between 2007-2017, 78 novel adult cancer agents were approved by the U.S. Food and Drug Administration,1 but none of those drugs were researched to determine effectiveness for pediatric cancers.

That is about to change on August 18 when the RACE Act – The Research to Accelerate Cures and Equity for Children Act – goes into effect. Passed in 2017, the RACE Act amends the existing PREA – Pediatric Research Equity Act – and eliminates the exemption from PREA requirements for cancer drugs that have orphan status. The new law requires pediatric evaluation of new drugs and biologics intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of pediatric cancer.

Clinical research companies and their pediatric research specialists, including PRA Health Sciences, will be called on to support pharmaceutical and biotech companies as they sponsor the required research for pediatric oncology indications.

“We are now 60 days away from the RACE Act going into effect, which has created a scramble to develop pediatric study plans for oncology studies,” said Dr. Mark Sorrentino, VP, The Center for Pediatric Clinical Development at PRA Health Sciences. “Here at PRA,
we have been preparing for the RACE Act since it was passed in 2017, so we are able to quickly and effectively support our clients and sponsors looking to conduct this research. We have brought together a highly credentialed team internally to serve as hands-on consultants in the development and execution of pediatric research plans.”

PRA’s Center for Pediatric Clinical Development and the team working on the RACE Act implementation include Dr. Sorrentino as well as Dr. Martine Dehlinger-Kremer, VP, Scientific Affairs, Pediatric Subject Matter Expert; Dr. Jacqui Whiteway, Senior Pediatric Strategy Liaison; Jo Dewhurst, LLB Dip; and Missy Hansen, MSN, APRN, CNP-Pediatrics, Pediatric Strategy Liaison. Together, with the addition of dozens of other PRA researchers and pediatric specialists, this designated team of experts is ready to utilize their collective experience in pediatric clinical development to support RACE Act-focused initiatives.

“Parents and pediatric oncologists need to have confidence that the therapies and treatments they are giving to their children are safe and effective for fighting cancer in pediatric patients,” Dr. Dehlinger-Kremer said. “The RACE Act is pushing all of us – drug developers, researchers, and medical care teams – to find the best treatments possible for children and their families, and to develop treatments that are specifically tailored to children.”

With the RACE Act going into effect, the law has caught up with the critical need for drug developers to focus on pediatric oncology.

  • Since 1980, only four oncology drugs were first approved for use in children2
  • Only 4 percent of funding spent on cancer research is directed toward childhood cancer3
  • Cancer drugs approved by the FDA take a median of 6.5 years to go from first clinical trial in adults to the first trial in children4
  • While considered a rare condition, 46 children are diagnosed with cancer each day5 and those patients, their families, and their medical teams need more treatments suitable for pediatric indications

“From a research perspective, there is so much more we can do to improve kids’ lives,” Dr. Sorrentino said. “PRA has conducted more than 130 pediatric studies in the last five years, and our promise, to the kids and their families, is to work quickly and safely, specifically with them in mind, to develop treatment options that will be effective for our smallest patients. It’s going to take a collective team effort between drug developers and researchers – we are ready for that challenge.”

For more information on the RACE Act, visit https://prahs.com/centers/the-center-for-pediatric-clinical-development/race-act. If you’d like to speak with one of PRA’s pediatric oncology experts, please reach out to us at https://prahs.com/contact/capabilities.

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

MEDIA INQUIRIES: Laurie Hurst, Director, Communications and Public Relations
hurstlaurie@prahs.com | +1 (919) 786-8435

References

  1. Hwang T.J., et al. Pediatric trials for cancer therapies with targets potentially relevant to pediatric cancers. Journal National Cancer Institute (2020) 112(3): djz207.
  2. Coalition Against Childhood Cancer. Childhood Cancer Fact Library (2017). https://cac2.org/childhood-cancer-fact-library-2017/#:~:text=Since%201980%2C%20only%20four%20drugs,use%20in%20high%2Drisk%20neuroblastoma.
  3. https://nationalpcf.org/facts-about-childhood-cancer/
  4. Dylan V. Neel, David S. Shulman, Steven G. DuBois. Timing of first-in-child trials of FDA-approved oncology drugs. European Journal of Cancer, 2019; 112: 49 DOI: 10.1016/j.ejca.2019.02.011.
  5. www.childrenscause.org

Crown Bioscience Hosts Innovative Virtual AACR 2020 Conference and Tradeshow

New Oncology and Immuno-Oncology Preclinical Research to be Presented at Virtual AACR Event

CrownBio Virtual AACR 2020

Register now for CrownBio’s Virtual AACR 2020 event

SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) — Crown Bioscience today announced their innovative AACR 2020 conference and tradeshow. The virtual event, which runs from June 22-25, will incorporate all of the features of a major scientific conference, with keynote speakers, access to CrownBio’s AACR 2020 posters, as well as a tradeshow booth.

To coincide with the AACR Virtual Annual Meeting II, this unique forum will feature the publication of CrownBio’s 13 internal and collaborative AACR 2020 posters, covering a range of preclinical oncology and immuno-oncology topics including tumor organoids and organoid engineering, imaging syngeneics and tumor homografts, and novel humanized drug target models, with poster authors on hand to answer all delegate questions.

The event is free to attend, registration is required at CrownBio.com/AACR20.

Highlights from the Keynote Theater comprise a presentation on accelerating drug discovery with patient-derived organoids (PDO) from Dr. Henry Li, CrownBio chief scientific officer, in addition to further presentations on biomarker discovery, in silico applications for in vitro drug discovery, and immunotherapy toxicology assessment platforms.

“We’re committed to furthering scientific discussion and drug discovery despite the challenges we face globally”, said Gavin Cooper, executive director of marketing at CrownBio. “Our innovative event experience is designed to fully replicate as close to a physical conference experience as possible, with live access to all of our resources, posters, and scientific teams”.

The event also features a Scientific Lounge for questions and real-time discussion with scientific staff. The Tradeshow Booth provides access to a wide range of CrownBio resources, showcasing products and services including organoids, biomarker discovery, bioinformatics, and patient-derived xenograft (PDX) models. Registration for the free event is open now at CrownBio.com/AACR20.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:

Media Enquiries:

Crown Bioscience

Jody Barbeau

pr@crownbio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2e34cb8b-be2b-4be4-b596-1e33d74cd138